Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13118001 | 0.83 | KDM4E (0.64) | KDM4EALDH1A1CNR1TP53THRB | |
| SCHEMBL13621171 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1CNR1TP53MAPT | |
| SCHEMBL8154739 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1CNR1TP53THRB | |
| SCHEMBL10576036 | 0.81 | ALDH1A1 (0.81) | KDM4EALDH1A1CNR1SIGMAR1MAPT | |
| SCHEMBL17937010 | 0.80 | ALDH1A1 (0.59) | KDM4EALDH1A1CNR1TSHRFNTA | |
| SCHEMBL4163306 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1CNR1TP53THRB | |
| SCHEMBL10574538 | 0.80 | ALDH1A1 (0.58) | KDM4EALDH1A1CNR1FNTAFNTB | |
| SCHEMBL1306448 | 0.78 | CYP1A2 (0.58) | KDM4EALDH1A1SIGMAR1MAPTTSHR | |
| SCHEMBL1305923 | 0.78 | HRH1 (0.59) | TP53THRBSIGMAR1 | |
| SCHEMBL12120399 | 0.78 | L3MBTL1 (0.71) | ALDH1A1THRBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | KDM4E 920/4885ALDH1A1 2589/4885CNR1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.